Luxdegalutamide

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameLuxdegalutamide
Drug Alias NameARV-766JSB-462
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionAndrogen Receptor degraders
TargetsAndrogen Receptor
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesArvinas LLC
China Registration ClassN/A

Develop Information

Active CompaniesNovartis AgPatheon Inc-Toronto Region OperationsCatalent Greenville Inc +[5] 
Inactive CompaniesN/A
Active IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia